Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Use risk-based approach to monitor trials, US FDA recommends

This article was originally published in Clinica

Executive Summary

The US FDA has issued final guidance on how medical device should oversee their clinical investigations that advocates adopting a risk-based approach to monitoring.

You may also be interested in...



EU Review Gets Under Way For Curative Vision Loss Gene Therapy

GenSight Biologics believes Lumevoq could become the first curative treatment for Leber hereditary optic neuropathy.

EU: Vifor Tries Again With Avacopan Using ‘More Powerful’ Data

Vifor Pharma has resubmitted a marketing application for avacopan to the European Medicines Agency – this time for an unconditional approval.

New EU Approvals

The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include two new products, including Novartis's Adakveo for preventing recurrent vaso-occlusive crises in patients with sickle cell disease. The list, which contains information dating back to January 2018, comprises brand name, generic name, company, therapeutic indication, date of marketing authorization announcement and product type (eg, medicine, vaccine, biologic).

Topics

UsernamePublicRestriction

Register

LL1134786

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel